Becton, Dickinson and Company Notes to Consolidated Financial Statements — (Continued) Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues. As discussed in Note 10, the Company completed its acquisition of Bard on December 29, 2017. Bard's operating results were included in the Company’s consolidated results of operations beginning on January 1, 2018. (a) Amounts presented in 2017 are associated with certain product offerings that were moved from the Medical segment to the Interventional segment in order to align with the reportable segment structure that became effective beginning in the second quarter of fiscal year 2018. 71 (Millions of dollars) 2019 2018 2017 United States International Total United States International Total United States International Total Medical Medication Delivery Solutions $ 2,048 $ 1,811 $ 3,859 $ 1,892 $ 1,752 $ 3,644 $ 1,378 $ 1,434 $ 2,812 Medication Management Solutions 2,104 525 2,629 1,957 513 2,470 1,843 452 2,295 Diabetes Care 573 538 1,110 564 541 1,105 546 510 1,056 Pharmaceutical Systems 392 1,073 1,465 357 1,040 1,397 328 929 1,256 Total segment revenues $ 5,116 $ 3,947 $ 9,064 $ 4,770 $ 3,846 $ 8,616 $ 4,095 $ 3,325 $ 7,419 Life Sciences Preanalytical Systems $ 774 $ 784 $ 1,558 $ 761 $ 792 $ 1,553 $ 741 $ 730 $ 1,471 Diagnostic Systems 672 875 1,547 678 858 1,536 622 756 1,378 Biosciences 485 709 1,194 475 766 1,241 455 684 1,139 Total segment revenues $ 1,931 $ 2,368 $ 4,300 $ 1,914 $ 2,416 $ 4,330 $ 1,818 $ 2,170 $ 3,988 Interventional Surgery (a) $ 1,098 $ 299 $ 1,397 $ 946 $ 245 $ 1,192 $ 577 $ 89 $ 666 Peripheral Intervention (a) 787 602 1,389 594 451 1,045 14 6 19 Urology and Critical Care 797 342 1,140 544 256 800 — — — Total segment revenues $ 2,682 $ 1,244 $ 3,926 $ 2,084 $ 953 $ 3,037 $ 591 $ 95 $ 685 Total Company revenues $ 9,730 $ 7,560 $ 17,290 $ 8,768 $ 7,215 $ 15,983 $ 6,504 $ 5,589 $ 12,093 Table of Contents